International Clinical Trial: 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131976) titled '16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer' on Sept. 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Second Affiliated Hospital Zhejiang University School of Medicine

Condition: Advanced Mid-to-Low Rectal Cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-10-01

Target Sample Size: Experimental group:51;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=339269

Published by HT Digital Content Services with permission fr...